(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Esteem Stuffed Gaming Workstations to Consider - 2The most effective method to Quick Track Your Outcome in Advanced Showcasing with a Web-based Degree
- 3Virtual Domains d: A Survey of \Inundation and Ongoing interaction Mechanics\ Computer game
- 4The most effective method to Oversee Unsold SUVs in the Car Business
- 5Treason trial of South Sudan's suspended VP is further eroding peace deal, UN experts say
- Bismuth’s haredi draft bill won’t change enlistment, IDI expert tells 'Post'
- A Couple of Reasonable Guitars for 2024
- Eco-Accommodating Kitchen Machines: 4 Picks for a Manageable Home
- A decade after Brazil’s deadly dam collapse, Indigenous peoples demand justice on the eve of COP30
- Pick Your #1 game to observe
- People who talk with their hands seem more clear and persuasive – new research
- Remain Fit and Sound with These Exercise Fundamentals
- Investigating the Medical advantages of Aloe Vera
- The Way to Monetary Health: Individual budget Change
